Core Viewpoint - Corning Jereh Pharmaceutical-B (09966) saw a significant increase of over 6%, currently trading at 10.89 HKD with a transaction volume of 10.4175 million HKD, following the announcement of a new drug clinical trial application for JSKN033, a combination therapy for advanced cervical cancer [1] Group 1: Clinical Trial Announcement - Corning Jereh Pharmaceutical-B announced that the clinical trial application for JSKN033, a high-concentration subcutaneous compound formulation consisting of a bispecific antibody-drug conjugate targeting HER2 and a PD-L1 immune checkpoint inhibitor, has been officially accepted by the National Medical Products Administration (NMPA) [1] - The JSKN033-202 trial is an open-label, multicenter, Phase II clinical trial aimed at evaluating the safety, efficacy, and pharmacokinetic/pharmacodynamic characteristics of JSKN033 in combination with platinum-based chemotherapy, with or without Bevacizumab, for patients with advanced cervical cancer [1] - All patients in the trial will receive treatment with JSKN033 in combination with either Cisplatin or Carboplatin, and the choice of platinum drug and whether to combine with Bevacizumab will be determined by the researchers based on the specific conditions of the patients [1]
港股异动 | 康宁杰瑞制药-B(09966)涨超6% 近日SKN033的一项II期临床试验IND申请获受理